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rimary biliary cirrhosisThe disease entity today widely called ‘primary biliary cirrho-
is’ was ﬁrst described by Addison & Gull in 1851 [1] and Hanot in
876 [2]. One hundred years after its ﬁrst description, MacMahon
 Thannhauser proposed the term ‘xanthomatous biliary cirrho-
is’ for this disease based on the typical xanthoma formation with
ccumulation of cholesterol esters in the skin around the eyes in
ssociation with inﬂammatory destruction of small intrahepatic
ile ductules leading to a biliary type cirrhosis [3]. Xanthoma for-
ation, however, is not a very common sign in this disorder. This
ay be the reason why the term ‘primary biliary cirrhosis’, pro-
osed one year later for the same disorder by Ahrens et al. [4],
ained wider acceptance when most patients were presenting with
dvanced liver disease.
 Editor’s note: This article is being published jointly in American Journal of Gas-
roenterology, Clinical Gastroenterology and Hepatology, Clinics and Research in
epatology and Gastroenterology, Digestive and Liver Disease, Gastroenterology,
ut, Hepatology and Journal of Hepatology.
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mary biliary cirrhosis’ as many of her patients were free of cirrhosis
at the time of diagnosis and the mean survival was 5 and a half
years (3–11) even for the fatal cases, whereas many asymptomatic
patients would survive more than 10 years [5]. The term ‘primary
biliary cirrhosis’ remained an issue of concern as reﬂected by the
name change proposal of Rubin, Schaffner and Popper in 1965 with
their paper ‘Primary biliary cirrhosis – Chronic non-suppurative
destructive cholangitis’ [6]. S. Sherlock wisely commented on this
new name: “. . .a  better one, although it is unlikely that it will
replace the more popular, although inaccurate, one of primary bil-
iary cirrhosis” [7]. She was  right, again. And even 40 years later, the
European [8] and American [9] Clinical Practice Guidelines still used
the term ‘primary biliary cirrhosis’ even though it was  an anachro-
nism and did not accurately reﬂect the natural history of disease in
the vast majority of patients as it is today.
The early diagnosis of primary biliary cirrhosis has dramati-
cally improved with the more accurate measurements of markers
of cholestasis and improvements in the detection of the classic
serologic hallmark, anti-mitochondrial antibodies. Furthermore,
the prognosis has dramatically improved with the introduction of
orthotopic liver transplantation in the 1970s and 1980s, and of
ursodeoxycholic acid (UDCA, 13–15 mg/kg daily) treatment in the
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980s and 1990s. Today, two out of three patients diagnosed with
rimary biliary cirrhosis and treated with UDCA have an expected
urvival not different from the general population and only a minor-
ty will ever develop cirrhosis.
The pathogenesis of primary biliary cirrhosis remains enig-
atic although enormous progress has been made in unravelling
enetic, immunological and pathophysiological molecular mech-
nisms involved [10–13]. This has also led to new therapeutic
pproaches which are now under evaluation [14,15].
On 23–24 May, 2014, the 2nd European Association for the
tudy of the Liver (EASL) Monothematic Conference on Primary
iliary Cirrhosis took place in Milan, Italy. On this occasion, patient
epresentatives from the UK and Germany, Robert Mitchell-Thain
nd Ingo van Thiel, representing numerous national patient groups
rom different parts of the world requested to change the name of
primary biliary cirrhosis’ to “correct the inaccuracy” and “remove
he cirrhosis stigma” as well as all the misunderstanding, disadvan-
ages and discriminations emanating from this misnomer in daily
ife of the patients.
This initiative was based on former discussions at a meeting with
nternational patient advocates and medical experts led by Raoul
oupon of France during the EASL International Liver Congress 2014
n London, and based in part on worldwide survey by patient sup-
ort groups performed among >1200 patients with primary biliary
irrhosis.
E-mail discussions among experts in the ﬁeld before the meet-
ng, as well as intense discussions during the EASL Monothematic
onference in Milan with continual e-mail exchanges after the
eeting has led to the widespread view among the vast majority
f worldwide experts that; (1) the name ‘primary biliary cirrhosis’
hould be changed [as advocated by Dame Sheila Sherlock in 1959].
n addition, the following proposals found broad support among
he discussants; (2) the acronym ‘PBC’ should be kept if possible;
3) a simple and short term should be used (imperfection accept-
ble) as long as the exact pathogenesis of primary biliary cirrhosis
emained undeﬁned and, therefore, an ‘ideal’ replacement is not
vailable.
In parallel with the growing patient support from Europe and
he U.S., several surveys were performed among international
xperts in the ﬁeld. Among EASL-selected committee members
nd senior reviewers of the EASL Guidelines for management of
holestatic liver diseases (n = 15), 100% agreed to a name change
or primary biliary cirrhosis and 100% voted to keep the abbrevia-
ion ‘PBC’. 60% preferred ‘primary biliary cholangitis’, 20% ‘primary
iliary cholangiopathy’, and 20% various other names. Among inter-
ational experts from the American Association for the Study of
iver Disease (AASLD), Asian Paciﬁc Association for the Study of
he Liver (APASL) and EASL [outside the EASL committees] (n = 16),
8% agreed to a name change for primary biliary cirrhosis and 88%
oted to keep the abbreviation ‘PBC’. 56% preferred ‘primary biliary
holangitis’, 13% ‘primary biliary cholangiopathy’, and 38% various
ther names. Among Japanese experts (n = 18), 100% agreed to a
ame change for primary biliary cirrhosis and 78% voted to keep
he abbreviation PBC. 61% preferred ‘primary biliary cholangitis’,
8% ‘primary biliary cholangiopathy’, and 11% various other names.
hus, considering that imperfection was acceptable in name ﬁnd-
ng, ‘primary biliary cholangitis’ found the broadest support as the
ew name for PBC among experts worldwide.
Our goal, as physicians, is to help and heal our patients both
ctively at the bedside but also passively in everyday social chal-
enges as patients balance their personal lives with their clinical
eeds. Our misuse of the name ‘cirrhosis’ is counterproductive to
ur support and our role as physicians. We  should also note that the
hange of name for an autoimmune disease is not without prece-
ence: Wegener’s granulomatosis for example is now known as
ranulomatous polyangiitis. Disease 47 (2015) 924–926 925
The proposal for a name change of primary biliary cirrhosis
to ‘primary biliary cholangitis’ was approved by the EASL Gover-
ning Board in November 2014, by the AASLD Governing Board in
April 2015 and by the American Gastroenterological Association
(AGA) Governing Board in July 2015. A vote of the APASL Governing
Board and the United European Gastroenterology (UEG) Governing
Board was pending at the moment this article was  written, whereas
support by respected Governing Board members from both associ-
ations was  provided beforehand.
What are the next steps? The World Health Organization (WHO)
is asking medical professionals for the ﬁrst time to help in the revi-
sion process of the diagnosis and symptom codes (International
Classiﬁcation of Diseases 11th Revision, ICD-11).
The medical representatives of the “Name Change Initiative for
PBC” – with support of the international primary biliary cirrhosis
patient groups – will take responsibility to submit the joint proposal
of international experts around the world for the name ‘primary
biliary cholangitis’.
We are aware of the imperfection of the new simple name and
agree that alternative proposals like primary small bile duct cholan-
gitis, primary intrahepatic cholangitis, primary small bile duct
cholangiopathy, primary biliary/peripheral (destructive) cholangi-
tis, or primary cholangiohepatitis may  come somewhat closer to
what we  think this inﬂammatory liver disorder is about. However,
we would kindly remind all critics of the fate of Hans Popper’s care-
fully chosen ‘chronic non-suppurative destructive cholangitis’ – too
difﬁcult according to the late Dame Sheila Sherlock. It failed to reach
sufﬁcient support.
‘Primary biliary cholangitis’ is a tautology (“saying the same
thing twice”), some critics say. But is that true? ‘Cholangitis’ ade-
quately describes the dense inﬂammatory inﬁltrates around small
damaged interlobular bile ductules. Recent experimental evidence
suggests that hydrophobic bile acids in bile, the major biliary
organic solutes, may  play a crucial role in the initiation of inﬂamma-
tion in primary biliary cirrhosis [16–21]. Future research will teach
us whether we have chosen a simple and, beyond that, reasonable
name.
The new term ‘primary biliary cholangitis’ will lead to confu-
sion in daily clinical practice with other forms of immune-mediated
cholangitis such as primary sclerosing cholangitis (PSC), some crit-
ics say. Indeed, the term ‘cholangitis’ is a general description of an
inﬂammatory disorder of the intra- and/or extrahepatic bile ducts
as is ‘cirrhosis’ for the description of replacement of normal liver
tissue by scar tissue. The name change for primary biliary cirrho-
sis offers the unique opportunity for new awareness campaigns
among medical professionals as well as patient groups to draw
more attention to immune-mediated biliary diseases like PBC or
PSC and, ultimately, their early correct diagnosis and treatment.
From ‘cirrhosis’ to ‘cholangitis’ – the change has critical impli-
cations for patients. It removes the stigmata of cirrhosis and its
implications of alcohol abuse. It removes the stigmata of a poor
prognosis. Its removal reminds patients that they are living with
this syndrome, not dying of it. Its removal improves their oppor-
tunities in the workplace and in their everyday social lives. Thus,
we sincerely call on all medical professionals and all patients and
their families and friends worldwide to use from this moment on
the name “primary biliary cholangitis” for the disease known by its
abbreviation PBC! We  owe  this to our patients and to further our
role as caring physicians.
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